The Swedish Medical Products Agency has approved ALK-Abelló' A/S' tablet-based immunotherapy, GRAZAX®, for the treatment of grass pollen allergy. ALK-Abelló will now submit applications for GRAZAX® in other European countries using the Mutual Recognition Procedure.